The move follows promising but early data presented at ASCO.

LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.

Any hopes of differentiation could come down to side effects.

Crunch time approaches for UroGen.

Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.

A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.

Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.

After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.

The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.